X
Xianming Deng
Researcher at Xiamen University
Publications - 166
Citations - 10877
Xianming Deng is an academic researcher from Xiamen University. The author has contributed to research in topics: Medicine & Kinase. The author has an hindex of 41, co-authored 147 publications receiving 8384 citations. Previous affiliations of Xianming Deng include Chinese Academy of Sciences & Scripps Research Institute.
Papers
More filters
Journal ArticleDOI
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett,Elena J. Edelman,Sonja J. Heidorn,Christopher Greenman,Christopher Greenman,Anahita Dastur,King Wai Lau,Patricia Greninger,I. Richard Thompson,Xi Luo,Jorge Soares,Qingsong Liu,Francesco Iorio,Francesco Iorio,Didier Surdez,Li Chen,Randy J. Milano,Graham R. Bignell,Ah Ting Tam,Helen Davies,Jesse A. Stevenson,Syd Barthorpe,Stephen R. Lutz,Fiona Kogera,Karl P. Lawrence,Anne McLaren-Douglas,Xeni Mitropoulos,Tatiana Mironenko,Helen Thi,Laura Richardson,Wenjun Zhou,F Jewitt,Tinghu Zhang,Patrick O’Brien,Jessica L. Boisvert,Stacey Price,Wooyoung Hur,Wanjuan Yang,Xianming Deng,Adam Butler,Hwan Geun Choi,Jae Won Chang,José Baselga,Ivan Stamenkovic,Jeffrey A. Engelman,Sreenath V. Sharma,Sreenath V. Sharma,Olivier Delattre,Julio Saez-Rodriguez,Nathanael S. Gray,Jeffrey Settleman,P. Andrew Futreal,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Sridhar Ramaswamy,Ultan McDermott,Cyril H. Benes +57 more
TL;DR: It was found that mutated cancer genes were associated with cellular response to most currently available cancer drugs, and systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.
Journal ArticleDOI
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio,Francesco Iorio,Theo A. Knijnenburg,Theo A. Knijnenburg,Daniel J. Vis,Graham R. Bignell,Michael P. Menden,Michael P. Menden,Michael Schubert,Nanne Aben,Nanne Aben,Emanuel Gonçalves,Syd Barthorpe,Howard Lightfoot,Thomas Cokelaer,Thomas Cokelaer,Patricia Greninger,Ewald van Dyk,Han Chang,Heshani de Silva,Holger Heyn,Xianming Deng,Regina K. Egan,Qingsong Liu,Tatiana Mironenko,Xeni Mitropoulos,Laura Richardson,Jinhua Wang,Tinghu Zhang,Sebastian Moran,Sergi Sayols,Maryam Soleimani,David Tamborero,Nuria Lopez-Bigas,Nuria Lopez-Bigas,Petra Ross-Macdonald,Manel Esteller,Manel Esteller,Nathanael S. Gray,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Cyril H. Benes,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Julio Saez-Rodriguez,Julio Saez-Rodriguez,Ultan McDermott,Mathew J. Garnett +48 more
TL;DR: It is reported how cancer-driven alterations identified in 11,289 tumors from 29 tissues can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs.
Journal ArticleDOI
Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang,Francisco Adrian,Wolfgang Jahnke,Sandra W. Cowan-Jacob,Allen G. Li,Roxana E. Iacob,Taebo Sim,Taebo Sim,John T. Powers,John T. Powers,Christine Dierks,Fangxian Sun,Gui Rong Guo,Qiang Ding,Barun Okram,Yongmun Choi,Amy Wojciechowski,Xianming Deng,Guoxun Liu,Gabriele Fendrich,André Strauss,Navratna Vajpai,Stephan Grzesiek,Tove Tuntland,Yi Liu,Badry Bursulaya,Mohammad Azam,Mohammad Azam,Paul W. Manley,John R. Engen,George Q. Daley,George Q. Daley,Markus Warmuth,Nathanael S. Gray +33 more
TL;DR: The results show that therapeutically relevant inhibition of Bcr–Abl activity can be achieved with inhibitors that bind to the myristate-binding site and that combining allosteric and ATP-competitive inhibitors can overcome resistance to either agent alone.
Journal ArticleDOI
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
Peter S. Hammerman,Martin L. Sos,Alex H. Ramos,Chunxiao Xu,Amit Dutt,Wenjun Zhou,Lear E. Brace,Brittany Woods,Wenchu Lin,Jianming Zhang,Xianming Deng,Sang Min Lim,Stefanie Heynck,Martin Peifer,Jeffrey R. Simard,Michael S. Lawrence,Robert C. Onofrio,Helga B. Salvesen,Danila Seidel,Thomas Zander,Johannes M. Heuckmann,Alex Soltermann,Holger Moch,Mirjam Koker,Frauke Leenders,Frauke Leenders,Franziska Gabler,Silvia Querings,Sascha Ansén,Elisabeth Brambilla,Christian Brambilla,Philippe Lorimier,Odd Terje Brustugun,Åslaug Helland,Iver Petersen,Joachim H. Clement,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Erich Stoelben,Juergen Wolf,David G. Beer,Ming-Sound Tsao,Megan Hanna,Megan Hanna,Charlie Hatton,Charlie Hatton,Michael J. Eck,Pasi A. Jänne,Bruce E. Johnson,Wendy Winckler,Heidi Greulich,Heidi Greulich,Adam J. Bass,Jeonghee Cho,Daniel Rauh,Nathanael S. Gray,Kwok-Kin Wong,Eric B. Haura,Roman K. Thomas,Matthew Meyerson,Matthew Meyerson +61 more
TL;DR: Findings suggest that gain-of-function mutations in DDR2 are important oncogenic events and are amenable to therapy with dasatinib, and provide a rationale for designing clinical trials with the FDA-approved drug d asatinib in patients with lung SCCs.
Journal ArticleDOI
Identification of a Selective and Direct NLRP3 Inhibitor to Treat Inflammatory Disorders
Hua Jiang,Hongbin He,Yun Chen,Wei Huang,J.-G. Cheng,Jin Ye,Aoli Wang,Aoli Wang,Jinhui Tao,Chao Wang,Qingsong Liu,Qingsong Liu,Tengchuan Jin,Wei Jiang,Xianming Deng,Rongbin Zhou +15 more
TL;DR: Treatment with CY-09 shows remarkable therapeutic effects on mouse models of cryopyrin-associated autoinflammatory syndrome (CAPS) and type 2 diabetes and indicates that NLRP3 can be targeted in vivo to combatNLRP3-driven diseases.